WHO vaccine-preventable diseases: monitoring system. 2019 global summary

Last updated 15-July-2019 (data as of 1-July-2019)
Next overall update Winter 2019
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 41'3301 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 46'2401 Child (under 5 years) mortality rate: 132

Population data in thousands3

  2018  2017  2016  2015  2014  2000  1990  1980 
Total population 67'142  66'727  66'298  65'860  65'423  58'923  57'134  56'209 
Births 775  779  785  791  797  696  778  686 
Surviving infants 772  776  782  788  794  692  772  678 
Pop. less than 5 years 3'977  4'007  4'044  4'087  4'098  3'551  3'824  3'382 
Pop. less than 15 years 11'869  11'767  11'662  11'562  11'470  11'215  10'836  11'816 
Female 15-49 years 30'169  30'215  30'261  30'298  30'347  28'184  28'353  26'575 

Number of reported cases

(Click for retrospective incidence data for United Kingdom of Great Britain and Northern Ireland (the))
Diphtheria
ChartChart
  15 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  1'216  364  558  91  133  104  28'228  147'962 
Mumps
ChartChart
  1'398  2'360  974  1'008  2'958  1'089 
Pertussis
ChartChart
  3'423  5'097  7'085  5'207  4'046  866  16'605  22'924 
Polio*
 
Rubella
ChartChart
  15  75 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  18  30 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for United Kingdom of Great Britain and Northern Ireland (the))
Vaccine year result method % card seen                                                
BCG         
DTP1         
DTP3          94  94  94  95  95  91  85 
IPV1         
HepB_BD         
HepB3         
Hib3          94  94  94  95  95  91 
JapEnc         
MCV1          92  92  92  93  93  88  89 
MCV2          88  88  89  89  89  76 
MenA         
PCV1         
PCV2          94  94  94  94  95 
PCV3          92  92  92  93  93 
Pol3          94  94  94  95  95  91  90 
Rota1         
RotaC          91  90  90  89 
RCV1          92  92  92  93  93 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid July 2020

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for United Kingdom of Great Britain and Northern Ireland (the))
DTP1
ChartChart
  98  98  98  98  98  97  94  66 
DTP3
ChartChart
  94  94  94  95  95  91  84  41 
HepB3
ChartChart
 
HepB_BD
ChartChart
 
Hib3
ChartChart
  94  94  94  95  95  91 
IPV1
  98  98  98  98 
MCV1
ChartChart
  92  92  92  93  93  88  87  53 
MCV2
ChartChart
  88  88  89  89  89  76 
PCV3
ChartChart
  92  92  92  93  93 
Pol3
ChartChart
  94  94  94  95  95  91  92  81 
RCV1
ChartChart
  92  92  92  93  93  88  87  53 
RotaC
ChartChart
  91  90  90  89 

Click to download WHO-UNICEF coverage estimates data for PAB time series.
Click to download WHO-UNICEF coverage estimates data for HPV time series.

Number of districts in the country 175  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 90
From 80 to 89% 9
From 50 to 79% 1
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2018 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes at birth to infants in areas of the country with TB incidence >= 40/100,000 or with a parent or grandparent born in a high incidence country
DTaPHibHepBIPV 8, 12, 16 weeks; Yes
DTaPIPV 3 years and 4 months; Yes and pregnant women from 16 weeks
HepB_Pediatric birth; 4 weeks; 1 year; Yes Babies at high risk of contracting Hep B also get 3 doses of hexavalent vaccine as part of the routine infant programme
HibMenC 1 year; Yes
HPV 12-13 years; +6-24 months; Yes females only; catch-up available up to 18 years of age
Influenza_Adult >65 years; Yes and adults with chronic conditions, pregnant women, healthcare workers, residents living in long-term care facilities, other risk groups
Influenza_Pediatric 2-9 years; Yes and children with chronic conditions
MenACWY-135 conj 14 years; Yes catch up available to 25 years of age
MenB 8, 16 weeks; 1 year; Yes
MenC_conj 12 weeks; Yes
MMR 1, 3 years and 4 months; Yes
Pneumo_conj 8, 16 weeks; 1 year; Yes
Pneumo_ps 65 years; Yes and risk groups from 2-65 years
Rabies 1st contact; 7, 28 days; Yes for individuals at continous & frequent risk of exposure to Rabies virus
Rotavirus 8, 12 weeks; Yes
TdIPV 14 years; Yes
Zoster 70, 78 years; Yes and also catch-up cohort at 78 years

Immunizaton indicators

Indicator Expected answer 2018  2017  2016  2015  2014  2013  2012 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number +5 years  5 years from current year (i.e. 2018/19 to 2022/23)  2016-2020  2017-2018       
Nº of districts with microplans that include activities to raise immunization coverage number 195  221  221      151  152 

System performance

Total Nº districts in country number 175  175      174  176  176 
Nº districts with DTP3 coverage >=80% number 173  171  173  172  172  175  176 
% of districts with DTP3 coverage >=80% From 0 to 100% 99  98      99  99  100 
Nº districts with measles (MCV1) coverage >=95% number 32  55  61  74  89  67  33 
% of districts with MCV1 coverage >=95% From 0 to 100% 18  31      51  38  19 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND   Yes  Yes  Yes  Yes  Yes   
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR   Yes  Yes  Yes  Yes  Yes   

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2019 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  UN Inter-agency Group for Child Mortality Estimation (https://childmortality.org/data)  
 3  "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.